title: Response to Denosumab Treatment for 2 Years in an Adolescent With Osteoradionecrosis.
abstract: Radiotherapy, an essential component of cancer treatment, is not without risk to bone, particularly to the immature or growing skeleton. Known side effects range from post-radiation osteitis to osteoradionecrosis. We report the case of a 14-year-old male patient undergoing denosumab treatment, a new antiresorptive agent, for osteoradionecrosis. The patient exhibited fractures and associated pain and functional limitations secondary to radiation for the treatment of an embryonal rhabdomyosarcoma of prostate grade III administered at age 5 years. After treatment with denosumab, the pain disappeared, bone remodeling markers dramatically declined, bone mass increased, and pathological bone scan findings resolved without adverse effects or new fractures.
authors.affiliation: Medicine Department, University of Seville, Seville, Spain.
authors.forename: M Angeles
authors.initials: MA
authors.lastname: Vázquez
authors.affiliation: Medicine Department, University of Seville, Seville, Spain.|Bone Metabolism Unit, Department of Internal Medicine, "Virgen Macarena" University Hospital, Seville, Spain.
authors.forename: Ramón
authors.initials: R
authors.lastname: Pérez-Temprano
authors.affiliation: Medicine Department, University of Seville, Seville, Spain.
authors.forename: M José
authors.initials: MJ
authors.lastname: Montoya
authors.affiliation: Bone Metabolism Unit, Department of Internal Medicine, "Virgen Macarena" University Hospital, Seville, Spain.|University of Seville, Seville, Spain.
authors.forename: Mercè
authors.initials: M
authors.lastname: Giner
authors.affiliation: University of Seville, Seville, Spain.|Orthopaedics and Traumatology Department, "Virgen Macarena" University Hospital, Seville, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Carpio
authors.affiliation: Medicine Department, University of Seville, Seville, Spain.|Bone Metabolism Unit, Department of Internal Medicine, "Virgen Macarena" University Hospital, Seville, Spain.
authors.forename: Ramon
authors.initials: R
authors.lastname: Pérez-Cano
mesh_terms: D000293:Adolescent; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling / Q000187:drug effects; D000069448:Denosumab / Q000008:administration & dosage*; D050723:Fractures, Bone / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D010025:Osteoradionecrosis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D011859:Radiography; D011878:Radiotherapy / Q000009:adverse effects; D018233:Rhabdomyosarcoma, Embryonal / Q000000981:diagnostic imaging / Q000532:radiotherapy
chemical_list: D015415:Biomarkers; D000069448:Denosumab
keywords: ADOLESCENT; BONE MINERAL DENSITY; DENOSUMAB; OSTEORADIONECROSIS; PATHOLOGICAL FRACTURES